BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29032615)

  • 1. Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications.
    Orive-Ramos A; Seoane S; Ocaña A; Pandiella A; Montero JC
    Mol Oncol; 2017 Dec; 11(12):1788-1805. PubMed ID: 29032615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node.
    Seoane S; Montero JC; Ocaña A; Pandiella A
    Oncogene; 2016 May; 35(21):2756-65. PubMed ID: 26364598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
    Xiao J; Xu M; Hou T; Huang Y; Yang C; Li J
    Mol Med Rep; 2015 Sep; 12(3):3249-3256. PubMed ID: 25975261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphatidylethanolamine-binding protein 4 is associated with breast cancer metastasis through Src-mediated Akt tyrosine phosphorylation.
    Li H; Huang F; Fan L; Jiang Y; Wang X; Li J; Wang Q; Pan H; Sun J; Cao X; Wang X
    Oncogene; 2014 Sep; 33(37):4589-98. PubMed ID: 24276246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer.
    de Alava E; Ocaña A; Abad M; Montero JC; Esparís-Ogando A; Rodríguez CA; Otero AP; Hernández T; Cruz JJ; Pandiella A
    J Clin Oncol; 2007 Jul; 25(19):2656-63. PubMed ID: 17602072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
    McKnight BN; Viola-Villegas NT
    Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SRC inhibition prevents P-cadherin mediated signaling and function in basal-like breast cancer cells.
    Ribeiro AS; Nobre AR; Mendes N; Almeida J; Vieira AF; Sousa B; Carvalho FA; Monteiro J; Polónia A; Fonseca M; Sanches JM; Santos NC; Seruca R; Paredes J
    Cell Commun Signal; 2018 Nov; 16(1):75. PubMed ID: 30404626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Src-family kinase inhibitors block early steps of caveolin-1-enhanced lung metastasis by melanoma cells.
    Ortiz R; Díaz J; Díaz-Valdivia N; Martínez S; Simón L; Contreras P; Lobos-González L; Guerrero S; Leyton L; Quest AFG
    Biochem Pharmacol; 2020 Jul; 177():113941. PubMed ID: 32240650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2.
    Esparís-Ogando A; Díaz-Rodríguez E; Montero JC; Yuste L; Crespo P; Pandiella A
    Mol Cell Biol; 2002 Jan; 22(1):270-85. PubMed ID: 11739740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma.
    Sun J; Wang X; Tang B; Liu H; Zhang M; Wang Y; Ping F; Ding J; Shen A; Geng M
    Theranostics; 2018; 8(12):3256-3267. PubMed ID: 29930727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
    Garmendia I; Pajares MJ; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba II; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga LM; Agorreta J
    Am J Respir Crit Care Med; 2019 Oct; 200(7):888-899. PubMed ID: 31166114
    [No Abstract]   [Full Text] [Related]  

  • 13. SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
    Larsen SL; Laenkholm AV; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    PLoS One; 2015; 10(2):e0118346. PubMed ID: 25706943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
    Teng Y; Cai Y; Pi W; Gao L; Shay C
    J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.
    Sun Y; Lin X; Aske JC; Ye P; Williams C; Abramovitz M; Leyland-Jones BR
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1241-1256. PubMed ID: 31541266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.
    Young AI; Law AM; Castillo L; Chong S; Cullen HD; Koehler M; Herzog S; Brummer T; Lee EF; Fairlie WD; Lucas MC; Herrmann D; Allam A; Timpson P; Watkins DN; Millar EK; O'Toole SA; Gallego-Ortega D; Ormandy CJ; Oakes SR
    Breast Cancer Res; 2016 Dec; 18(1):125. PubMed ID: 27931239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sublethal doxorubicin promotes migration and invasion of breast cancer cells: role of Src Family non-receptor tyrosine kinases.
    Mohammed S; Shamseddine AA; Newcomb B; Chavez RS; Panzner TD; Lee AH; Canals D; Okeoma CM; Clarke CJ; Hannun YA
    Breast Cancer Res; 2021 Jul; 23(1):76. PubMed ID: 34315513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation.
    Centa A; Rodríguez-Barrueco R; Montero JC; Pandiella A
    Mol Oncol; 2018 Jun; 12(7):1061-1076. PubMed ID: 29683256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.